About Antibody Drug Conjugates
ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.
Technavio’s analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Antibody Drug Conjugates Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Antibody Drug Conjugates Market: F. Hoffmann-La Roche AG, Seattle Genetics Inc., and Takeda Pharmaceutical Company.
Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, and Zymeworks.
Commenting on the report, an analyst from Technavio’s team said: “Strategic alliances, in terms of collaboration and licensing, help co-develop and commercialize drugs in different regions. Co-development agreements between companies enable the use of technical expertise from both companies. It also allows the use of regulatory and development experience gained by one company for the support of the pipeline candidates of the other company. Such agreements ensure the in-flow of adequate funds for both the companies and help reduce the liability costs of individual companies in case of failures, attracting more venture investments.”
According to the report, products in the late pipeline stages will likely be launched during the forecast period. Some of these products include glembatumumab vedotin by Seattle Genetics, trastuzumab by Synthon Biopharmaceuticals, and SGN-35 by Takeda Pharmaceuticals. Some molecules are in the Phase I/II, preclinical, and discovery stages. ADCETRIS is currently under clinical trials for additional indications such as frontline mature T-cell lymphomas, B-cell lymphomas, and CD30-expressing conditions.
Further, the report states that the high developmental costs of antibody conjugates negatively impact the growth of the market.
F. Hoffmann-La Roche AG, Seattle Genetics Inc., Takeda Pharmaceutical Company, AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, Zymeworks.